Mostrar el registro sencillo del ítem

dc.contributor.authorLondono, Maria-Carlota
dc.contributor.authorRiveiro-Barciela, Mar
dc.contributor.authorAhumada, Adriana
dc.contributor.authorMunoz-Gomez, Raquel
dc.contributor.authorRoget, Merce
dc.contributor.authorDevesa-Medina, Maria J
dc.contributor.authorSerra, Miguel Angel
dc.contributor.authorNavascues, Carmen A
dc.contributor.authorBaliellas, Carme
dc.contributor.authorAldamiz-Echevarria, Teresa
dc.contributor.authorGutierrez, Maria L
dc.contributor.authorPolo-Lorduy, Benjamin
dc.contributor.authorCarmona, Isabel
dc.contributor.authorBenlloch, Salvador
dc.contributor.authorBonet, Lucia
dc.contributor.authorGarcia-Samaniego, Javier
dc.contributor.authorJimenez-Perez, Miguel
dc.contributor.authorMoran-Sanchez, Senador
dc.contributor.authorCastro Iglesias, Angeles 
dc.contributor.authorDelgado Blanco, Manuel 
dc.contributor.authorGea-Rodriguez, Francisco
dc.contributor.authorMartín-Granizo Barrenechea, Ignacio 
dc.contributor.authorMontes, Maria Luisa
dc.contributor.authorMorano Amado, Luis 
dc.contributor.authorCastano, Manuel A
dc.contributor.authorde Los Santos, Ignacio
dc.contributor.authorLaguno, Montserrat
dc.contributor.authorLosa, Juan Emilio
dc.contributor.authorMontero-Alonso, Marta
dc.contributor.authorRivero, Antonio
dc.contributor.authorde Alvaro, Cristina
dc.contributor.authorManzanares, Amanda
dc.contributor.authorMallolas, Josep
dc.contributor.authorBarril, Guillermina
dc.contributor.authorGonzalez-Parra, Emilio
dc.contributor.authorGarcia-Buey, Luisa
dc.date.accessioned2022-01-25T12:16:13Z
dc.date.available2022-01-25T12:16:13Z
dc.date.issued2019
dc.identifier.issn1932-6203
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759177/pdf/pone.0221567.pdfes
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31550267es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15905
dc.description.abstractBACKGROUND AND AIMS: Limited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r +/- DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015. MATERIAL AND METHODS: Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and tolerability data were collected from medical records. RESULTS: Data from 135 patients with a mean age (SD) of 58.3 (11.4) years were analyzed: 92.6% GT1 (81.6% GT1b and 17.6% GT1a) and 7.4% GT4, 14 (10.4%) HIV/HCV co-infected, 19.0% with fibrosis F3 and 28.1% F4 by FibroScan(R), 52.6% were previously treated with pegIFN and RBV. 11.1%, 14.8% and 74.1% of patients had CKD stage IIIb, IV and V respectively. 68.9% of patients were on hemodialysis; 8.9% on peritoneal dialysis and 38.5% had history of renal transplant. A total of 125 (96.2%) of 135 patients were treated with 3D, 10 (7.4%) with 2D and 30.4% received RBV. The overall intention-to-treat (ITT) sustained virologic response at week 12 (SVR12) was 92.6% (125/135) and the overall modified-ITT (mITT) SVR12 was 99.2% (125/126). The SVR12 rates (ITT) per sub-groups were: HCV mono-infected (91.7%), HCV/HIV co-infected (100%), GT1 (92.0%), GT4 (100%), CKD stage IIIb (86.7%), stage IV (95%) and stage V (93%). Among the 10 non-SVR there was only 1 virologic failure (0.7%); 4 patients had missing data due lost to follow up (3.0%) and 5 patients discontinued 3D/2D regimen (3.7%): 4 due to severe adverse events (including 3 deaths) and 1 patient s decision. CONCLUSIONS: These results have shown that 3D/2D regimens are effective and tolerable in patients with advanced CKD including those in dialysis with GT 1 or 4 chronic HCV mono-infection and HIV/HCV coinfection in a real-life cohort. The overall SVR12 rates were 92.6% (ITT) and 99.2% (mITT) without clinically relevant changes in eGFR until 12 weeks post-treatment. These results are consistent with those reported in clinical trials.en
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshDrug Therapy*
dc.subject.meshMiddle Aged*
dc.subject.meshRibavirin*
dc.subject.meshSulfonamides*
dc.subject.meshCoinfection*
dc.subject.meshRitonavir*
dc.subject.meshGenotype*
dc.subject.meshCarbamates*
dc.subject.meshHepatitis C*
dc.subject.meshRenal Insufficiency*
dc.subject.meshHumans*
dc.subject.meshTreatment Outcome*
dc.subject.meshUracil*
dc.subject.meshAnilides*
dc.subject.meshMacrocyclic Compounds*
dc.subject.meshHepacivirus*
dc.subject.meshRenal Dialysis*
dc.subject.meshRetrospective Studies*
dc.subject.meshAged*
dc.subject.meshAntiviral Agents*
dc.subject.meshHIV Infections*
dc.titleEffectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD studyen
dc.typeArtigoes
dc.identifier.doi10.1371/journal.pone.0221567
dc.identifier.pmid31550267
dc.identifier.sophos32298
dc.issue.number9es
dc.journal.titlePLoS Onees
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Dixestivoes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Medicina Internaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Dixestivoes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Medicina Internaes
dc.rights.accessRightsopenAccesses
dc.subject.decsresultado del tratamiento*
dc.subject.decsribavirina*
dc.subject.decsantivíricos*
dc.subject.decscompuestos macrocíclicos*
dc.subject.decsanilidas*
dc.subject.decsdiálisis renal*
dc.subject.decsestudios retrospectivos*
dc.subject.decsmediana edad*
dc.subject.decsfarmacoterapia*
dc.subject.decscoinfección*
dc.subject.decsritonavir*
dc.subject.decsinfecciones por VIH*
dc.subject.decssulfonamidas*
dc.subject.decsanciano*
dc.subject.decscarbamatos*
dc.subject.decsgenotipo*
dc.subject.decshepatitis C*
dc.subject.decshumanos*
dc.subject.decsuracilo*
dc.subject.decsinsuficiencia renal*
dc.subject.decsHepacivirus*
dc.subject.keywordCHUACes
dc.subject.keywordCHUVIes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number14es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional